Phosphodiesterase 10A levels are related to striatal function in schizophrenia: a combined positron emission tomography and functional magnetic resonance imaging study

Pharmacological inhibition of phosphodiesterase 10A (PDE10A) is being investigated as a treatment option in schizophrenia. PDE10A acts postsynaptically on striatal dopamine signaling by regulating neuronal excitability through its inhibition of cyclic adenosine monophosphate (cAMP), and we recently...

Descripción completa

Detalles Bibliográficos
Autores principales: Persson, Jonas, Szalisznyó, K., Antoni, G., Wall, A., Fällmar, D., Zora, H., Bodén, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210243/
https://www.ncbi.nlm.nih.gov/pubmed/31119377
http://dx.doi.org/10.1007/s00406-019-01021-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210243/
https://www.ncbi.nlm.nih.gov/pubmed/31119377
http://dx.doi.org/10.1007/s00406-019-01021-0

Ejemplares similares